

SANGAMO BIOSCIENCES CORPORATE FACT SHEET

Sangamo Biosciences, Inc. (www.sangamo.com; Nasdaq: SGMO) is the worldwide leader in the research, development and commercialization of engineered zinc finger DNA-binding protein transcription factors (ZFP TFs) for the regulation of gene expression. The company offers the only approach to altering gene expression within a cell or patient that imitates the natural mode of gene regulation and has the ability to specifically turn genes both on and off.

Sangamo intends to commercialize its technology across many applications in the multi-billion dollar markets of human therapeutics and pharmaceutical discovery.

The company was founded in 1995 and is headquartered in Richmond, California.

TECHNOLOGY

Sangamo's core technology enables the engineering of zinc finger DNA binding proteins (ZFPs) that mimic the behavior and characteristics of ZFPs that occur naturally in multiple species. By engineering ZFPs that recognize a specific DNA sequence and linking these with an appropriate functional domain that naturally up- or down-regulates gene expression, Sangamo has created ZFP transcription factors that can control gene expression and, consequently, cell function. For example, the technology can be used to stimulate the formation of new blood vessels in tissues.

Sangamo's ZFP TFs provide distinct advantages over other therapeutic approaches because they directly regulate a cell's own genes. This ability to specifically target any gene in the genome and directly regulate it provides a new therapeutic platform for the post-genomic era. Another technical advantage of the technology is that it enables gene regulation in a "natural" fashion — allowing the up- or down-regulation of all of a gene's encoded splice variants in the ratios that are normally found in nature. In addition, regulation of genes as they occur in the cell provides an alternative for working with genes for which patents may already exist.

Sangamo has patents issued and pending worldwide to utilize ZFP technology to regulate genes in cells.

CUSTOMERS

More than 25 leading pharmaceutical and biotechnology companies have used Sangamo's ZFP TFs to regulate genes, including Bristol-Myers Squibb Company, Glaxo SmithKline, Johnson & Johnson, Merck and Pfizer, . In addition, Sangamo has formed strategic collaboration partnerships with companies including Edwards Lifesciences, Onyx Pharmaceuticals and Avigen Inc. Companies employ Sangamo's technology to research and validate drug targets and create their own proprietary products as well as develop products collaboratively. Due to the platform nature of its technology, Sangamo has retained the vast majority of its intellectual property rights in its strategic collaboration deals.

BUSINESS STRATEGY

Sangamo's business model includes the nonexclusive licensing of its ZFP TF technology in the areas of cell lines for high throughput screening of small molecule drugs, monoclonal antibody generation and protein production. These licensing agreements generate near-term revenue that enables the company to maintain a strong balance sheet and fund its long-term objective of commercializing ZFP TF human therapeutic products. Sangamo's ZFP TF platform technology provides the company with enormous commercial potential by enabling it to partner with different organizations on a gene-by-gene basis. The company has a strong balance sheet with cash reserves of over \$50 million, and a low cash burn-rate.

EXECUTIVE MANAGEMENT

Sangamo's board of directors and senior management team are among the most experienced in the biotech industry having worked for leading companies and institutions such as Eli Lilly, Novartis, Genentech, Chiron and Tularik. Edward Lanphier, who has more than 20 years of experience in the pharmaceutical industry, is the founder of Sangamo and its President and Chief Executive Officer. The company has recruited outstanding scientists from some of the most prestigious labs in the world who are led by Dr. Carl Pabo, its Senior Vice President and Chief Scientific Officer, formerly of the Massachusetts Institute of Technology. Sangamo's senior management team also includes Peter Bluford, Vice President of Corporate Development, Casey Case, Ph.D., Vice President of Research, Tyler Martin, Vice President of Development, Janet Nibel, Vice President of Finance and Administration and Eric Rhodes, Senior Director of Commercial Development. A world-class scientific advisory board, including individuals from Johns Hopkins, Harvard Medical School and Rockefeller University, supports Sangamo's scientific efforts.